On December 7, 2018 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is reported to provide an update on the Phase 2 clinical trial of ProscaVax being hosted at Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard University (Press release, Oncbiomune, DEC 7, 2018, View Source [SID1234531944]). In the clinical trial, ProscaVax, the Company’s lead immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), is being evaluated for safety and efficacy in patients with low-risk localized prostate cancer compared to patients in "Active Surveillance."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OncBioMune has confirmed that a site visit is scheduled for December 19, 2018. This is the check-off meeting before beginning enrollment in the clinical trial, which is expected to transpire in the coming weeks.
"I’m very pleased to say that we are now staring down a major milestone for our company with the site visit to be followed by patient enrollment," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "Enrollment of the first patient in the study is not only a watershed moment for our company and stakeholders, but for the oncology community as a whole. This is the first Phase 2 clinical trial of its type evaluating a therapeutic immunotherapy vaccine in early stage prostate cancer, a stage in disease where patients are left with no options other than to wait for disease progression. We are optimistic that ProscaVax will demonstrate a meaningful benefit to these patients in great need and that ProscaVax will set a new benchmark as a front-line treatment for prostate cancer."